Page 1 | Search Results | Blood | American Society of Hematology

1-6 of 6

Sort by

Sort Order Select

Journal Articles

The Oral Proteasome Inhibitor Ixazomib, Alone and in Combination with Ibrutinib, Induces Lethality in Waldenstrom Macroglobulinemia Cells That Are Resistant to Ibrutinib

Aneel Paulus, MD, Alak Manna, PhD, Sharoon Akhtar, MPhil, Neeraj Kumar Singh, B.Tech, Ansu Kumar, MS, Kabya Basu, MS, Akshita Trivedi, B.Tech, Debapriya Majumdar, M.Sc., Taher Abbasi, MS, MBA, Shireen Vali, PhD, Vivek Roy, MD, Peter Martin, FRCPC, MD MS, Morton Coleman, MD, Anne J Novak, PhD, Stephen M Ansell, MD PhD, Sikander Ailawadhi, Asher A. Chanan-Khan, MD

Blood (2017) 130 (Supplement 1): 1260.

https://doi.org/10.1182/blood.V130.Suppl_1.1260.1260

Published: 2017

Journal Articles

Predicting Mechanisms of Ibrutinib-Resistance in Chronic Lymphocytic Leukemia (CLL) Using Computational-Based Modeling for Personalized Therapy with Clinical Validation

Leylah M. Drusbosky, PhD, Aneel Paulus, MD, Anne Quillet Mary, PhD, Loic Ysebaert, MD PhD, Ansu Kumar, MS, Neeraj Kumar Singh, B.Tech, Yashaswini Ullal, BE, Priyanka Bhargav, BE, Humera Azam, MS, Taher Abbasi, MS, MBA, Shireen Vali, PhD, Asher A. Chanan-Khan, MD, Christopher R. Cogle, MD

Blood (2017) 130 (Supplement 1): 4278.

https://doi.org/10.1182/blood.V130.Suppl_1.4278.4278

Published: 2017

Journal Articles

A Genomic Signature Predicting Venetoclax Treatment Response in Acute Myeloid Leukemia (AML) Identified By Protein Network Mapping and Validated By Ex Vivo Ddrug Sensitivity Testing

Blood (2017) 130 (Supplement 1): 2707.

https://doi.org/10.1182/blood.V130.Suppl_1.2707.2707

Published: 2017

Journal Articles

Predictive Simulation Modeling of Early T-Cell Precursor Acute Lymphoblastic Leukemia (ETP-ALL) Patient Genomics Identifies Targeted Combination Treatment Options

Leylah M. Drusbosky, PhD, Ansu Kumar, MS, Shwetha K, BE, Priyanka Bhargav, BE, Ashish Choudhary, MS, Soumyashree L, BE, Shivgonda C. Birajdar, MCA, Kunal Ghosh Roy, MS, Taher Abbasi, MS, MBA, Shireen Vali, PhD, Manju Sengar, MD DM, Girish Chinnaswamy, MD MRCP, Bijal D. Shah, MD, Christopher R. Cogle, MD

Blood (2017) 130 (Supplement 1): 2708.

https://doi.org/10.1182/blood.V130.Suppl_1.2708.2708

Published: 2017

Journal Articles

Personalized Therapy Design for Early T-Cell Precursor Acute Lymphoblastic Leukemia (ETP-ALL) Using Computational Biology Modeling with in Vitro Validation

Madeleine Turcotte, MS, Raphael Charles Bosse, BS, MD PhD, Kimberly E. Hawkins, PhD BS, Amy Meacham, MS, Vindhya Vijay, MS, Girish Chinnaswamy, MD MRCP, Manju Sengar, MD DM, Ansu Kumar, MS, Shwetha K, BE, Anisha Kamath, BT, Anjana T. Nair, MS, Karthik S. Raju, MS, Taher Abbasi, MS, MBA, Shireen Vali, PhD, Christopher R. Cogle, MD, Leylah M. Drusbosky, PhD

Blood (2017) 130 (Supplement 1): 1448.

https://doi.org/10.1182/blood.V130.Suppl_1.1448.1448

Published: 2017

Journal Articles

Computational Biology Model of ETP-ALL Used to Accurately Classify ETP-ALL Vs Non ETP-ALL Patients with Genomic Input

Leylah M. Drusbosky, PhD, Ansu Kumar, MS, Shwetha K, BE, Sumanth Vasista, BE, Anuj Tyagi, MS, Swaminathan Rajagopalan, MT, Aftab Alam, MS, Taher Abbasi, MS, MBA, Shireen Vali, PhD, Girish Chinnaswamy, MD MRCP, Manju Sengar, MD DM, Bijal D. Shah, MD, Christopher R. Cogle, MD

Blood (2017) 130 (Supplement 1): 1449.

https://doi.org/10.1182/blood.V130.Suppl_1.1449.1449

Published: 2017

NARROW

The Oral Proteasome Inhibitor Ixazomib, Alone and in Combination with Ibrutinib, Induces Lethality in Waldenstrom Macroglobulinemia Cells That Are Resistant to Ibrutinib

Predicting Mechanisms of Ibrutinib-Resistance in Chronic Lymphocytic Leukemia (CLL) Using Computational-Based Modeling for Personalized Therapy with Clinical Validation

A Genomic Signature Predicting Venetoclax Treatment Response in Acute Myeloid Leukemia (AML) Identified By Protein Network Mapping and Validated By Ex Vivo Ddrug Sensitivity Testing

Predictive Simulation Modeling of Early T-Cell Precursor Acute Lymphoblastic Leukemia (ETP-ALL) Patient Genomics Identifies Targeted Combination Treatment Options

Personalized Therapy Design for Early T-Cell Precursor Acute Lymphoblastic Leukemia (ETP-ALL) Using Computational Biology Modeling with in Vitro Validation

Computational Biology Model of ETP-ALL Used to Accurately Classify ETP-ALL Vs Non ETP-ALL Patients with Genomic Input

Email alerts

ASH Publications

American Society of Hematology

The Oral Proteasome Inhibitor Ixazomib, Alone and in Combination with Ibrutinib, Induces Lethality in Waldenstrom Macroglobulinemia Cells That Are Resistant to Ibrutinib

Predicting Mechanisms of Ibrutinib-Resistance in Chronic Lymphocytic Leukemia (CLL) Using Computational-Based Modeling for Personalized Therapy with Clinical Validation

A Genomic Signature Predicting Venetoclax Treatment Response in Acute Myeloid Leukemia (AML) Identified By Protein Network Mapping and Validated By Ex Vivo Ddrug Sensitivity Testing

Predictive Simulation Modeling of Early T-Cell Precursor Acute Lymphoblastic Leukemia (ETP-ALL) Patient Genomics Identifies Targeted Combination Treatment Options

Personalized Therapy Design for Early T-Cell Precursor Acute Lymphoblastic Leukemia (ETP-ALL) Using Computational Biology Modeling with in Vitro Validation

Computational Biology Model of ETP-ALL Used to Accurately Classify ETP-ALL Vs Non ETP-ALL Patients with Genomic Input

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only